Introduction
============

The liver is a common site of metastases and gastrointestinal-, lung- and breast cancers frequently give rise to liver metastases.[@b1-clep-3-011] Liver metastasis is usually considered to be a manifestation of end stage disease. However, in patients with colorectal cancer (CRC) metastases, the disease often presents with oligometastases relatively early on and the liver is often the only site of metastasis. Hence, at the time of CRC-diagnosis, 15% of patients have metastases to the liver and in approximately 75% of these, the metastases are confined to the liver.[@b2-clep-3-011] In general, systemic therapy is the preferred treatment for most patients with liver metastases, but patients with a limited number and size of the metastases and with favorable histology, especially CRC, should be considered for focal therapy.[@b3-clep-3-011]--[@b7-clep-3-011] A large number of systemic therapies for patients with metastatic cancer have been introduced during the last 10 years and over the same period surgery and nonsurgical techniques for focal ablation of metastases in the liver have improved considerably.[@b8-clep-3-011]

The Danish National Board of Health launched The National Cancer Treatment Plans I and II in 2000 and 2005 aiming at improving cancer treatment in the country.[@b9-clep-3-011] The major issues were improvements in diagnostics, surgery, radiation therapy, and chemotherapy for cancer, and major government investments have followed the program. Assessing whether these efforts have resulted in real improvement in terms of survival outcomes is thus of great interest. We therefore conducted a cohort study in Northern Denmark to study time changes in survival in patients with liver metastases synchronously to CRC and non-CRC during 1998 to 2009. We chose only to evaluate patients with synchronous liver metastases because metachronous metastases are known to be incompletely registered. Due to differences in biology and therapy options, the study evaluated patients with CRC and non-CRC liver metastases separately.

Material and methods
====================

The study was conducted in the Central and the North Denmark Regions (2 of 5 Danish regions), with a combined population of 1.8 million. The National Health Service provides tax-supported health care for all inhabitants of Denmark, guaranteeing free access to hospitals. A 10-digit civil registration number has been assigned to all residents by the Central Office of Civil Registration since 1968.[@b10-clep-3-011] This number, unique to each Danish resident, is used in all Danish registries, allowing unambiguous individual-level data linkage.

Identification of liver metastases cancer patients
--------------------------------------------------

Through the Danish National Registry of Patients (DNRP), we identified all patients who had a first time diagnosis of liver metastases in the period January 1, 1998 through December 31, 2009 and no previous cancer diagnosis recorded in the DNRP. DNRP contains information about all admissions from nonpsychiatric hospitals in Denmark since 1977.[@b11-clep-3-011] Outpatient and emergency room visits at hospitals have been included since 1995. This registry includes information on civil registration number, dates of admission and discharge, surgical procedure(s) performed, and up to 20 diagnoses from each hospital contact. Diagnoses have since 1994 been classified according to the International Classification of Diseases (ICD) 10th edition. The ICD-10 codes used to identify patients with liver metastases was C78.7 and additional codes used for identification of the primary cancers were C18-21 (CRC/anal cancer) and C00-17; and C22-97 (non-CRC).[@b12-clep-3-011] We restricted our study population to patients considered to have synchronous metastases, defined by being registered with a code for a primary cancer at date of liver metastasis diagnosis or within 60 days thereafter.

Survival
--------

Survival status and eventual date of death for all included patients was obtained through the Civil Registration System. Since 1968, this system has kept electronic records, updated daily, on date of birth, date of emigration, and vital status for all residents. Data linkage was performed using the civil registration number as identification number.

Statistical analysis
--------------------

Because we defined our population as patients with a primary cancer diagnosed at date of liver metastasis diagnosis or up to 60 days thereafter, we started our follow-up 60 days after metastasis diagnosis. We followed each patient until emigration, death, or 25 June 2010, whichever came first. To visualize crude survival we constructed Kaplan--Meier curves stratified according to period of diagnosis (1998--2000, 2001--2003, 2004--2006, and 2007--2009). We estimated 1-, 3-, and 5-year survival. In the latter periods we estimated 3- and 5-year survival using a hybrid analysis in which we included the actual survival for as long as possible and then estimated the conditional probability of surviving thereafter based on the corresponding survival experience of patients in the previous period (ie, using a period analysis technique).[@b13-clep-3-011] To compare mortality over time we used Cox proportional hazards regression analysis with 1998 to 2000 as the reference period to estimate the MRR and the corresponding 95% confidence interval (CI) adjusting for age (15--59 years, 60--74 years, 75+ years) and gender. The assumptions of proportional hazards were examined graphically by plotting observed and simulated paths of the standardized score process.

Analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).

Results
=======

The study cohort comprised a total number of 1021 patients identified with synchronous liver metastases during the 12 year period 1998 to 2009 in the Central and North Denmark Regions who all survived at least 60 days after date of diagnosis. The largest group of patients (n = 541; 53.0%) were diagnosed with CRC as primary cancer whereas the remaining non-CRC patients represented a variety of tumor sites (n = 480; 47.0%). In the same time period 15,097 patients were registered with primary CRC (colon cancer or rectal cancer; ICD: C18-19 or C20-21) in the Central and North Denmark Regions. The distribution of patients according to the primary tumor site is listed in [Table 1](#t1-clep-3-011){ref-type="table"}. The non-CRC group was dominated by patients with primary gastro-intestinal and lung cancer, whereas only 2.2% had a primary breast cancer. In the total cohort the median age was 66.8 (range 15.3--95.3) years ([Figure 1](#f1-clep-3-011){ref-type="fig"}) with a male/female distribution of 54%/46%. The median age was 67.7 (range 27.0--93.2) and 66.2 (range 15.3--95.3) years and the male/female distribution 53%/47% and 55%/45% for the CRC and non-CRC cohorts, respectively.

For patients with synchronous liver metastases, the overall survival improved over the 12-year period ([Table 2](#t2-clep-3-011){ref-type="table"}). This was most pronounced during 2007 to 2009. Over the time period 1998 to 2009, the 5-year survival improved from 3% (95% CI: 1%--6%) to 10% (95% CI: 6%--14%) (predicted value). The 5-year survival of CRC-patientsimproved from 1% (95% CI: 0%--5%) to 11% (95% CI: 6%--18%) ([Table 3](#t3-clep-3-011){ref-type="table"}) whereas the increase of survival for non-CRC patients was 5% (95% CI: 1%--10%) to 8% (95% CI: 4%--14%) ([Table 4](#t4-clep-3-011){ref-type="table"}).

MRRs adjusted for age and gender in 2007 to 2009 were 0.74 (95% CI: 0.60--0.92), 0.75 (95% CI: 0.62--0.91) and 0.75 (95% CI: 0.62--0.90) after 1, 3, and 5 years, respectively, compared with 1998--2000 ([Figure 2A](#f2-clep-3-011){ref-type="fig"}, [Table 2](#t2-clep-3-011){ref-type="table"}). For CRC patients ([Figure 2B](#f2-clep-3-011){ref-type="fig"}) the age and gender adjusted MRRs were 0.62 (95% CI: 0.45--0.85), 0.68 (95% CI: 0.52--0.88), and 0.66 (95% CI: 0.51--0.86) after 1, 3, and 5 years, respectively, over the same time period ([Table 3](#t3-clep-3-011){ref-type="table"}). For non-CRC patients the adjusted MRRs were 0.83 (95% CI: 0.62--1.11), 0.82 (95% CI: 0.62--1.08), and 0.81 (95% CI: 0.62--1.07), respectively ([Table 4](#t4-clep-3-011){ref-type="table"}).

Discussion
==========

In this population-based study from Northern Denmark we found that the prognosis in patients with liver metastases diagnosed synchronously with CRC or other solid tumors improved from 1998 to 2009. Overall, 1-, 3- and 5-year mortality decreased approximately 25% for the total group and among CRC patients the mortality decreased nearly 35%.

Different factors affected the interpretation of our results. We conducted a population-based study in a uniform health care system with a well-defined catchment area and had data on a population of patients treated over more than a decade. Moreover, we had virtually complete follow-up for mortality. However, our study also had limitations. The registration of liver metastases in DNRP may not be complete and may have changed during the study period. Since completeness of liver metastases in DNPR may differ by disease severity our survival estimates could be inaccurate. Nevertheless, the annual number of CRC patients with synchronous liver metastases did not increase during our study period which speaks against major differences in completeness with time. Therefore, we do not expect differences in completeness of registration to explain the improved survival in CRC patients. Among non-CRC patients the annual number of patients increased. If this was caused by inclusion of more patients with less advanced liver metastases diagnosed earlier the observed improvement in survival among non-CRC patients could be explained by lead time bias. Furthermore, we only included patients with liver metastases at time of cancer diagnosis and did not include patients with liver metastases diagnosed after resection of the primary tumor (ie, metachronous metastases) so we are unable to evaluate the effect in these patients. In order to provide more up-to-date information on long-term survival we used a hybrid analysis rather than a traditional analysis. Traditionally, the 5-year survival would be derived only from patients who had been observed for 5 years or more, thereby not reflecting more recent improvements in survival. The weakness of the hybrid analysis is that it may not be as accurate as directly observed survival. However, since we based our predictions on the survival experience in the previous period of our study we expect these predictions to be conservative estimates of the improved survival.

Imaging technology used for diagnosis of liver metastases has improved during the period. Computer tomography and magnetic resonance imaging which are considered the best imaging modalities in diagnosis and staging of liver metastases have improved over time,[@b14-clep-3-011] and for ultrasound utilization of contrast enhancement has increased the diagnostic accuracy.[@b15-clep-3-011] However, since the numbers of new cases did not change for CRC, we find it unlikely that improvement of imaging technology is responsible for the entire increased number of non-CRC patients with liver metastases as noticed in the present study. In this regards, we find it most likely that the study population represents a steady-state population and that the survival benefit is caused by improved therapy.

An improvement in survival is likely to be a result of the many treatments that are offered to the patients over the entire course of the disease. During the time period of the present study a multidisciplinary team was introduced for treatment of liver tumors and the therapy for liver tumors was evolving over the period. Historical studies have shown that long-term survival can be achieved in patients undergoing surgical resection of oligometastases to the liver.[@b3-clep-3-011]--[@b5-clep-3-011] Patients who are technically operable should therefore be offered a surgical resection. Novel surgical techniques have increased the number of patients who are technically operable.[@b16-clep-3-011],[@b17-clep-3-011] However, only approximately 25% of patients with CRC liver metastases are amenable to surgical resection.[@b18-clep-3-011] Nonsurgical ablation techniques, such as radiofrequency ablation or stereotactic body radiation therapy are frequently used to treat patients with unresectable liver metastases in Denmark.[@b19-clep-3-011],[@b20-clep-3-011] Still, the efficacy of surgery and nonsurgical tumor ablation has never been proven in randomized trials.

Traditionally, metastatic cancer is treated by systemic therapies and chemotherapy has improved considerably during the last decade. For CRC patients, chemotherapy and targeted therapy to patients with metastatic cancer may improve survival, lessen symptoms related to the disease, improve quality of life and downsize liver-only metastases in patients with nonresectable metastases that potentially may become resectable.[@b21-clep-3-011] And for patients with metastatic non- CRC, new cytostatic agents, hormonal agents, and biological therapies have resulted in survival benefit.[@b22-clep-3-011]

In conclusion our study indicates an improvement in survival for liver metastases patients during the 12 years from 1998 to 2009. The survival gain for CRC liver metastasis patients may be a result of intensified efforts in the multidisciplinary care of patients who benefit from improved systemic therapy and more aggressive approach in resection or ablation of the liver metastases.
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###### 

Patients with synchronous liver metastasis by primary tumor site, Northern Denmark 1998 to 2009

  Site                             Frequency   Percent
  -------------------------------- ----------- ---------
  Colorectal (CRC)                 541         52.99
  Noncolorectal (non-CRC)          480         47.01
   Pancreas                        144         14.10
   Lung, bronchi, and trachea      130         12.73
   Stomach                         38          3.72
   Liver                           27          2.64
   Breast                          22          2.15
   Esophagus                       21          2.06
   Kidney                          19          1.86
   Gallbladder and biliary tract   16          1.57
   Other                           63          6.17
  Total                            1021        100.00

**Abbreviation:** CRC, colorectal carcinoma.

###### 

1-, 3-, and 5-year overall survival and mortality rate ratio (MRR) adjusted for age and gender for Danish patients with liver metastases stratified by period of diagnosis

                                                            Period of diagnosis                                                                                     
  --------------------------------------------------------- --------------------- ------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Number of cancer patients                                 190                   288                 239                                                           304
  Median age (years)                                        67                    67                  66                                                            68
  **1-year**                                                                                                                                                        
  Survival                                                  22% (16%--28%)        25% (20%--30%)      24% (19%--30%)                                                30% (25%--36%)
  MRR                                                       1 (reference)         0.96 (0.78--1.18)   0.88 (0.71--1.09)                                             0.76 (0.62--0.94)
  Adjusted MRR[\*](#tfn2-clep-3-011){ref-type="table-fn"}   1 (reference)         0.98 (0.79--1.20)   0.87 (0.70--1.08)                                             0.74 (0.60--0.92)
  **3-year**                                                                                                                                                        
  Survival                                                  5% (3%--9%)           7% (5%--11%)        5% (3%--9%)                                                   12% (8%--16%)[†](#tfn3-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)         0.94 (0.78--1.13)   0.91 (0.75--1.10)                                             0.77 (0.63--0.93)[†](#tfn3-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn2-clep-3-011){ref-type="table-fn"}   1 (reference)         0.96 (0.79--1.16)   0.91 (0.75--1.11)                                             0.75 (0.62--0.91)[†](#tfn3-clep-3-011){ref-type="table-fn"}
  **5-year**                                                                                                                                                        
  Survival                                                  3% (1%--6%)           5% (3%--7%)         4% (2%--7%)[†](#tfn3-clep-3-011){ref-type="table-fn"}         10% (6%--14%)[†](#tfn3-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)         0.93 (0.77--1.13)   0.90 (0.74--1.09)[†](#tfn3-clep-3-011){ref-type="table-fn"}   0.76 (0.63--0.92)[†](#tfn3-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn2-clep-3-011){ref-type="table-fn"}   1 (reference)         0.95 (0.79--1.15)   0.90 (0.74--1.10)[†](#tfn3-clep-3-011){ref-type="table-fn"}   0.75 (0.62--0.90)[†](#tfn3-clep-3-011){ref-type="table-fn"}

**Notes:** Adjusted for age and gender;

Predicted values.

###### 

1-, 3-, and 5-year overall survival and mortality rate ratio (MRR) adjusted for age and gender for the cohort of colorectal carcinoma liver metastasis patients stratified by period of diagnosis

                                                            Year of diagnosis                                                                                     
  --------------------------------------------------------- ------------------- ------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Number of cancer patients                                 103                 158                 120                                                           160
  Median age (years)                                        67                  67                  66                                                            69
  **1-year**                                                                                                                                                      
  Survival                                                  28% (20%--37%)      37% (30%--45%)      36% (27%--44%)                                                46% (37%--53%)
  MRR                                                       1 (reference)       0.85 (0.63--1.15)   0.86 (0.62--1.18)                                             0.65 (0.48--0.89)
  Adjusted MRR[\*](#tfn4-clep-3-011){ref-type="table-fn"}   1 (reference)       0.90 (0.67--1.22)   0.85 (0.61--1.17)                                             0.62 (0.45--0.85)
  **3-year**                                                                                                                                                      
  Survival                                                  5% (2%--10%)        11% (7%--17%)       9% (5%--15%)                                                  15% (9%--21%)[†](#tfn5-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)       0.82 (0.63--1.06)   0.86 (0.66--1.13)                                             0.69 (0.53--0.90)[†](#tfn5-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn4-clep-3-011){ref-type="table-fn"}   1 (reference)       0.87 (0.67--1.12)   0.87 (0.66--1.15)                                             0.68 (0.52--0.88)[†](#tfn5-clep-3-011){ref-type="table-fn"}
  **5-year**                                                                                                                                                      
  Survival                                                  1% (0%--5%)         6% (3%--11%)        6% (3%--12%)[†](#tfn5-clep-3-011){ref-type="table-fn"}        11% (6%--18%)[†](#tfn5-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)       0.79 (0.62--1.03)   0.84 (0.64--1.09)[†](#tfn5-clep-3-011){ref-type="table-fn"}   0.68 (0.52--0.88)[†](#tfn5-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn4-clep-3-011){ref-type="table-fn"}   1 (reference)       0.84 (0.65--1.08)   0.87 (0.66--1.14)[†](#tfn5-clep-3-011){ref-type="table-fn"}   0.66 (0.51--0.86)[†](#tfn5-clep-3-011){ref-type="table-fn"}

**Notes:** Adjusted for age and gender;

Predicted values.

###### 

1-, 3-, and 5-year overall survival and mortality rate ratio (MRR) adjusted for age and gender for the cohort of non-colorectal carcinoma liver metastasis patients stratified by period of diagnosis

                                                            Year of diagnosis                                                                                     
  --------------------------------------------------------- ------------------- ------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Number of cancer patients                                 87                  130                 119                                                           144
  Median age (years)                                        65                  65                  65                                                            67
  **1-year**                                                                                                                                                      
  Survival                                                  14% (8%--22%)       10% (6%--16%)       13% (7%--19%)                                                 14% (8%--20%)
  MRR                                                       1 (reference)       1.11 (0.83--1.48)   0.81 (0.60--1.09)                                             0.83 (0.62--1.11)
  Adjusted MRR[\*](#tfn6-clep-3-011){ref-type="table-fn"}   1 (reference)       1.11 (0.83--1.48)   0.81 (0.60--1.09)                                             0.83 (0.62--1.11)
  **3-year**                                                                                                                                                      
  Survival                                                  6% (2%--12%)        2% (1%--6%)         2% (0%--5%)                                                   8% (4%--14%)[†](#tfn7-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)       1.13 (0.86--1.50)   0.86 (0.65--1.15)                                             0.82 (0.62--1.08)[†](#tfn7-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn6-clep-3-011){ref-type="table-fn"}   1 (reference)       1.13 (0.86--1.50)   0.87 (0.65--1.15)                                             0.82 (0.62--1.08)[†](#tfn7-clep-3-011){ref-type="table-fn"}
  **5-year**                                                                                                                                                      
  Survival                                                  5% (1%--10%)        2% (1%--6%)         2% (.%--.%)[†](#tfn7-clep-3-011){ref-type="table-fn"}         8% (4%--14%)[†](#tfn7-clep-3-011){ref-type="table-fn"}
  MRR                                                       1 (reference)       1.11 (0.84--1.46)   0.86 (0.65--1.14)[†](#tfn7-clep-3-011){ref-type="table-fn"}   0.82 (0.62--1.08)[†](#tfn7-clep-3-011){ref-type="table-fn"}
  Adjusted MRR[\*](#tfn6-clep-3-011){ref-type="table-fn"}   1 (reference)       1.11 (0.84--1.47)   0.83 (0.62--1.10)[†](#tfn7-clep-3-011){ref-type="table-fn"}   0.81 (0.62--1.07)[†](#tfn7-clep-3-011){ref-type="table-fn"}

**Notes:** Adjusted for age and gender;

Predicted values.
